App-Quantinova.ai

Auditory rhythmic cueing changes motor control during walking in Parkinson’s disease

A. Islam - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Parkinson's disease

N/A

B lymphocytes may be protective in early Parkinson’s disease and in an animal model of dopaminergic cell death

K. Scott - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Beta burst coupling across the motor circuit in patients with Parkinson’s disease

G. Tinkhauser - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Brain Perfusion pattern linked to depressive state in Parkinson’s: An arterial spin labelling MRI study

Y. Xing - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Burden of Eye disease in Parkinson’s disease (PD)

N. Butt - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Age-Related Macular Degeneration

N/A

Can a novel digital pen system assist clinicians in the differential diagnosis of Parkinson’s disease?

M. Agarwal - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

CASPR2 antibody mediated autoimmune encephalitis presenting with profound chorea

S. Scotton - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Autoimmune Encephalitis

N/A

Categorising visual hallucinations in early Parkinson’s disease

B. Clegg - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Cerebrospinal fluid flow dynamics in Huntington’s disease evaluated by phase contrast MRI

F. Rodrigues - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Clinical predictors of screen-defined dementia in early Parkinson’s

F. Baig - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience

R.N. Taddei - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Alkaline phosphatase

Compensatory functional activations in early-stage Parkinson’s disease: a cross-sectional motor planning fMRI study

A. Martin-Bastida - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Cortical myoclonus explained by cerebellar dysfunction: Evidence from a unique case

L. Rocchi - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Could the rate of dopaminergic medications reduction affect outcome after STN-DBS?

S. Alusi - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

DBS neuromodulation reduces severe dystonic pain in children and young people

S. Perides - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cerebral Palsy

N/A

Decreased blood beta-Glucosidase activity and GBA mutations in Dystonia

S. Schreglmann - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dystonia

N/A

Distinct effects of apathy and dopamine on effort-based decision making in Parkinson’s disease

C. Le Heron - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Does the degree of improvement after deep brain stimulation surgery for Parkinson’s disease (PD) meet the patient’s expectations?

J. Candelario-Mckeown - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Does the Parkinson’s Kinetigraph change clinical practice?

S. Jones - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Dual task walking differentially affects toe clearance in Lewy body disease: A contributor to dynamic falls risk?

L. Alcock - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lewy body dementia

N/A

Filters

45280 Abstracts